The Curious Case Of The Ranbaxy-Teva Lipitor Deal; NY AG Reveals Hidden Provision
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York Attorney General obtains a $300,000 settlement with Ranbaxy and Teva for their agreement not to challenge each other’s market exclusivity rights; the arrangement was part of a deal that gave Teva a cut of Ranbaxy’s atorvastatin sales.